The Boston-based biopharmaceutical company is developing a pipeline of oligonucleotide, antibody, enzyme, protein, and peptide programs using its proprietary Endosomal Escape Vehicle (EEV™) platform. EEV™ therapeutics enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues, addressing current challenges associated with both large and small molecule therapeutics. The company's versatile and modular platform is being used to build a robust development portfolio of programs for the potential treatment of neuromuscular diseases, immunology, oncology, and diseases of the central nervous system.